Metronidazole B. Braun (Metronidazole)

Metronidazole enters anaerobic bacteria and protozoa and is reduced by intracellular electron‑transfer proteins to form nitro radicals. These reactive species damage DNA, inhibit nucleic acid synthesis, and disrupt essential metabolic pathways, resulting in irreversible cell death of the targeted microorganisms.

The dose and duration of Metronidazole B. Braun are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. No fixed dosing can be provided without a medical prescription.

The safety of Metronidazole B. Braun in pregnancy has not been definitively established; it should be used only when the potential benefit outweighs any possible risk to the fetus. Limited data suggest it passes into breast milk, so caution is advised and breastfeeding decisions should be made with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metronidazole is unique among anaerobic antibiotics because it is selectively activated within anaerobic cells, offering rapid bactericidal activity. Compared with clindamycin or beta‑lactam/beta‑lactamase inhibitor combinations, metronidazole often provides a narrower spectrum focused on anaerobes, which can reduce collateral impact on normal flora but may require combination therapy for mixed infections.

Metronidazole B. Braun should be stored at controlled room temperature, typically below 25 °C, in its original packaging. The container should be kept away from direct sunlight, moisture, and extreme temperature fluctuations to maintain product stability.

Metronidazole B. Braun is supplied as an intravenous solution and is administered directly into a vein by a qualified healthcare professional. The infusion rate and concentration are set by the prescriber according to the clinical situation and patient-specific factors.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, hepatic toxicity, and hematologic abnormalities like neutropenia. Patients should be monitored for neurological symptoms, skin reactions, and liver function during therapy.

Metronidazole B. Braun is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazoles, and in individuals who have consumed alcohol or are taking disulfiram due to the risk of a severe disulfiram‑like reaction. Caution is also advised for patients with severe hepatic or renal impairment.